ANTI-GRANZYME B CLONE 3M4 ZOOMAB RABBIT MONOCLONAL (C15-1669-281)

General description

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Specificity

Clone 3M4 is a ZooMAb^® rabbit recombinant monoclonal antibody that specifically detects human Granzyme B.

Immunogen

His-tagged full-length recombinant human Granzyme B expressed in E. coli.

Application

Quality Control Testing
Evaluated by Western Blotting with recombinant Human Granzyme B.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected recombinant Human Granzyme B.
Tested applications
Flow Cytometry Analysis: 1 μg from a representative lot detected Granzyme B in one million NK92 cells.
Affinity Binding Assay: A representative lot of this antibody bound recombinant human Granzyme B with a KD of 9.9 x 10-6 in an affinity binding assay.
Enzyme Immunoassay (ELISA) Analysis: A Serial of dilutions from a representative lot detected recombinant Human Granzyme B.
Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Evaluated by Western Blotting with recombinant Human Granzyme B.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected recombinant Human Granzyme B.

Target description

Granzyme B (UniProt: P10144; also known as EC:3.4.21.79, C11, CTLA-1, Cathepsin G-like 1, CTSGL1, Cytotoxic T-lymphocyte proteinase 2, Lymphocyte protease, Fragmentin-2, Granzyme-2, Human lymphocyte protein, HLP, SECT, T-cell serine protease 1-3E) is encoded by the GZMB (also known as CGL1, CSPB, CTLA1, GRB) gene (Gene ID: 3002) in human. Granzyme B, a serine protease of the peptidase S1 family, is synthesized with a signal peptide (aa 1-18) and a propeptide (aa 19-20) that are subsequently cleaved off to produce the active enzyme (aa 21-247). Granzyme B expression is regulated at both the transcriptional and translational levels and is influenced by many of the same factors that stimulate immune cell activation. Transcriptional activation of granzyme B within T lymphocytes involves activation of the T cell receptor and co-stimulation with cytokines. It is abundantly present in the cytosolic granules of cytotoxic T-cells and NK cells and activate caspase-independent pyroptosis when delivered into the target cells through the immunological synapse. Once delivered into the target cell, it acts by catalyzing the cleavage of gasdermin-E to release its pore-forming moiety. It is also linked to a caspase activation cascade that is responsible for apoptosis execution. This ZooMAbZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Zhang, Z., et al (2020). Nature. 579( 7799); 415-420; Boivin, WA., et al. (2009). Lab. Invest. 89; 1195-1120; Poe, M., et al. (1991). J. Biol. Chem. 266(1); 98-103).

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

Reconstitution

300 μg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.